Cipla Limited is trading higher by 2% at Rs 389 on reports that the pharmaceutical company won a patent case against Swiss drug maker in the Delhi High Court on Friday.
“Delhi High Court has ruled in favour of Cipla in a patent infringement case filed by Switzerland's Roche Holding AG over Cipla's cancer drug Erlocip,” the Reuters report suggests.
Roche accuses Cipla of infringing its patent on cancer drug Tarceva, which Cipla sells under the brand name Erlocip.
The stock opened at Rs 385 and touched lifetime high of Rs 390 on the National Stock Exchange. A combined 280,000 shares have changed hands on the counter so far on both the exchanges.
